http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102816732-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee877b65926d4f883d3871369925c785 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f35334ae6dc88f5937fec733e2bf32c |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 |
| filingDate | 2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87f36a710e812ac41d7904cbc3854119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f3f585cc4b3625a95a393a9f45c2bae |
| publicationDate | 2013-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102816732-B |
| titleOfInvention | MDCK cell line suitable for full suspended serum-free culture and its application in culturing of influenza virus and production of influenza virus vaccines |
| abstract | The invention discloses an MDCK cell line suitable for full suspended culture and an application of the MDCK cell line in culturing of influenza virus and production of influenza virus vaccines, and belongs to the field of biotechnology. The MDCK cell line suitable for full suspended culture is named MDCK-ZL2012 and its strain collection number is CGMCC No. 6210. The invention also provides a method for culturing influenza virus by the utilization of the cell line. By the adoption of the MDCK cell line provided by the invention, full suspended culture of MDCK cells in a serum-free medium is realized. Therefore, by the adoption of the MDCK cell line for culturing of influenza virus, on one hand, output of flu antigen virus is increased and the production cost of influenza virus is reduced; and on the other hand, the risk of exogenous factor pollution during the culturing process of influenza virus and an emergency reaction caused by the usage of the vaccines are reduced, and subsequent virus processing steps of clarification, microfiltration, ultrafiltration, purification and the like are made to be simpler and more feasible. |
| priorityDate | 2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.